Sean M. Hartig, Ph.D.
Picture

Sean M. Hartig, Ph.D.
Associate Professor
Positions
- Associate Professor
-
Medicine
Endocrinology, Diabetes, and Metabolism
Baylor College of Medicine
Houston, Texas US
- Associate Professor
-
Mol & Cell Biology
Baylor College of Medicine
Houston, TX US
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
Addresses
- BCM-Alkek Building for Biomedical Research (Lab)
-
ABBR-R612
Houston, TX 77030
United States
hartig@bcm.edu
Education
- Post-Doctoral Fellowship at Baylor College Of Medicine
- 10/2011 - Houston, Texas United States
- Molecular and Cellular Biology
- Post-Doctoral Fellowship at University Of Texas MD Anderson Cancer Center
- 06/2008 - Houston, Texas United States
- Cancer Biology
- PhD from Vanderbilt University
- 12/2006 - Nashville, Tennessee United States
- Chemical Engineering
- BS from North Carolina State University
- 05/2001 - Raleigh, North Carolina United States
- Chemical Engineering
Honors & Awards
- Nancy Chang, Ph.D. Award for Research Excellence
- Baylor College of Medicine
- Protege, The Academy of Medicine, Engineering and Science of Texas
- Norton Rose Fulbright Faculty Excellence Award in Teaching and Evaluation
- Baylor College of Medicine
Professional Interests
- Cellular Mechanisms of Obesity and Diabetes
Professional Statement
Obesity affects one in three adults worldwide and represents the most significant risk factor for type 2 diabetes, cardiovascular disease, and metabolic syndrome. We are interested in fundamental aspects of metabolic regulation, particularly how diet and environment act on fat cells to influence the co-morbidities of obesity. Recent efforts in our laboratory use modern combinations of mouse and human studies to examine the cell biology within adipose tissue and identify targets for the treatment of obesity, diabetes, and other metabolic disorders.We are always looking for energetic graduate students and postdoctoral fellows to join our group. Candidates are encouraged to reach out to Dr. Hartig for potential areas of collaboration.
Our lab recruits graduate students from the Cancer & Cell Biology, Genetics & Genomics, and Development, Disease Models & Therapeutics programs.
Websites
Selected Publications
- Felix JB, Cox AR, Hartig SM "Acetyl-CoA and metabolite fluxes regulate white adipose tissue expansion." Trends Endocrinol Metab. 2021;32:320-332.
- Cox AR, Masschelin PM, Saha PK, Felix JB, Sharp R, Lian Z, Xia Y, Chernis N, Bader DA, Kim KH, Li X, Yoshino J, Li X, Li G, Sun Z, Wu H, Coarfa C, Moore DD, Klein S, Sun K, Hartig SM "The rheumatoid arthritis drug auranofin lowers leptin levels and exerts anti-diabetic effects in obese mice." Cell Metab. 2022;34:1934-1936.
- Masschelin PM, Saha P, Ochsner SA, Cox AR, Kim KH, Felix JB, Sharp R, Li X, Tan L, Park JH, Wang L, Putluri V, Lorenzi PL, Nuotio-Antar AM, Sun Z, Kaipparettu BA, Putluri N, Moore DD, Summers SA, McKenna NJ, Hartig SM "Vitamin B2 enables regulation of fasting glucose availability." eLife. 2023;12:e84077.
Projects
- Developmental signals that regulate body fat distribution
- White adipose tissue is an endocrine organ that dynamically expands and contracts to meet the metabolic demands of the organism. It is found in the subcutaneous layer and distinct intra-abdominal depots. Excess abdominal fat is associated with insulin resistance, type 2 diabetes, and cardiovascular disease. In contrast, expansion of subcutaneous white adipose tissue depots is associated with normal insulin sensitivity and reduced incidence of obesity-linked conditions including ectopic fat deposition, hepatic steatosis (fatty liver), and type 2 diabetes. We are interested in transcriptional pathways that specify the patterning of white adipose tissue depots in normal development and obesity. These projects will ultimately explore pathways and signals that dictate the selective expansion of depot-specific fat cells.
Memberships
- Endocrine Society
- Member
- American Diabetes Association
- Member
Funding
- Metabolic Impacts of Type II Interferon Signals in Obesity - #R01DK114356 (08/18/2017 - 06/30/2026) Grant funding from NIH NIDDK
- The long-term goal of this project is to understand how inflammation contributes to the co-morbidities of obesity.
- Metabolic Impact of FGF-21 in Adipose Tissue and Liver of People Living With HIV - #R01DK126042 (09/20/2020 - 06/30/2025) Grant funding from NIH NIDDK
- The goal of this project is to understand how elevated FGF21 expression contributes to fatty liver disease in people living with HIV.
Log In to edit your profile